Inclusion Criteria:

- Healthy volunteers only

- Males/females ≥ 50 years and ≤ 65 years of age

- Cancer patients and inflammation patients (inflammation patients in study part 2 =
optional, in study part 3 mandatory)

- Males/females ≥ 30 and ≤ 80 years of age

- patients had an FDG PET/CT for detection, or staging, or restaging, or therapy
response assessment that still showed tumor mass with high certainty, for

1. NSCLC (non small cell lung cancer), or

2. adenocarcinoma of the breast (female patients) or

3. squamous cell cancer of head and neck and the cancer disease is
histologically confirmed.

4. Patients with confirmed/known inflammatory focus/foci after FDG-PET/CT
imaging

Exclusion Criteria:

- Exclusion criteria for all healthy volunteers and patients:

- any concomitant disease (for healthy volunteers) and for patients any concurrent
severe and/or uncontrolled and/or unstable other medical disease (e.g. poorly
controlled diabetes, congestive heart failure, myocardial infarction within 12
months prior to planned injection of BAY86-9596, unstable and uncontrolled
hypertension, chronic renal or hepatic disease, severe pulmonary disease) which
could compromise participation in the study

- For healthy volunteers and patients: known sensitivity to the study drug or
components of the preparation.

- tumor patients with known inflammatory disease, where images overlap
inflammatory lesions with tumor lesions